银屑病患者生物制剂累积暴露与癌症风险:来自以色列、意大利、西班牙、英国和爱尔兰的Psonet研究荟萃分析
该嵌套病例对照研究基于Psonet四个国家注册研究近6万人年观察,纳入728例癌症病例和2671例匹配对照,采用条件logistic回归和随机效应荟萃分析。结果显示,银屑病患者生物制剂累积暴露年限与首次癌症风险无显著关联(校正比值比每年1.02,95%置信区间0.92-1.13)。
要点
- 生物制剂累积暴露每年与癌症风险的校正比值比为1.02(95%置信区间0.92-1.13)。
- 将鳞状细胞癌和基底细胞癌纳入结局后结果相似。
- 真实临床实践中生物制剂长期暴露未显示与癌症风险升高相关。
核心结论
- 真实临床实践中银屑病患者生物制剂累积暴露年限在数年使用后似乎与癌症风险升高无关。
研究设计与样本
- 嵌套病例对照研究,由Psonet(欧洲银屑病注册研究)协作的四个国家研究参与,包括以色列医疗数据库以及意大利、西班牙和英国与爱尔兰的前瞻性队列,观察近6万人年。
- 病例为发生新发癌症的患者,排除既往癌症及良性或原位肿瘤患者;每个病例按出生年份、性别、地理区域和注册年份匹配4名无癌症对照。
- 对照随访至匹配病例的癌症诊断日期删失;各注册研究分别进行条件logistic回归,结果采用随机效应荟萃分析合并。
主要发现
- 共识别728例病例和2671例对照。
- 匹配后,三个注册研究中病例与对照的Charlson合并症指数存在差异,且英国皮肤科医师协会生物干预注册研究中既往补骨脂素-长波紫外线暴露和吸烟的患病率也存在差异。
- 首次癌症风险与生物制剂累积暴露无显著关联(校正比值比每年1.02,95%置信区间0.92-1.13)。
- 将鳞状细胞癌和基底细胞癌纳入结局后,结果相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 匹配后,三个注册研究中病例与对照的Charlson合并症指数存在差异,英国皮肤科医师协会生物干预注册研究中既往补骨脂素-长波紫外线暴露和吸烟的患病率也存在差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cancer risk following long-term exposure to systemic immunomodulatory therapies in patients with psoriasis is possible. OBJECTIVES: To assess a dose-response relationship between cumulative length of exposure to biological therapy and risk of cancer. METHODS: Four national studies (a healthcare database from Israel, and prospective cohorts form Italy, Spain and the U.K. and Republic of Ireland) collaborating through Psonet (European Registry of Psoriasis) participated in these nested case-control studies, including nearly 60 000 person-years of observation. 'Cases' were patients who developed an incident cancer. Patients with previous cancers and benign or in situ tumours were excluded. Four cancer-free controls were matched to each case on year of birth, sex, geographic area and registration year. Follow-up for controls was censored at the date of cancer diagnosis for the matched case. Conditional logistic regression was performed by each registry. Results were pooled using random-effects meta-analysis. RESULTS: A total of 728 cases and 2671 controls were identified. After matching, differences between cases and controls were present for the Charlson Comorbidity Index in all three registries, and in the prevalence of previous exposure to psoralen-ultraviolet A and smoking (the British Association of Dermatologists Biologic Interventions Register only). The risk of first cancers was not significantly associated with cumulative exposure to biologics (adjusted odds ratio per year of exposure 1·02, 95% confidence interval 0·92-1·13). Results were similar if squamous and basal cell carcinomas were included in the outcome. CONCLUSIONS: Cumulative length of exposure to biological therapies in patients with psoriasis in real-world clinical practice does not appear to be linked to a higher risk of cancer after several years of use.
引用
- Garcia-Doval I, Descalzo MA, Mason KJ, et al. Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta-analysis of Psonet studies from Israel, Italy, Spain, the U.K. and Republic of Ireland. Br J Dermatol. 2018. PMID: 29723914. doi:10.1111/bjd.16715
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。